A starnge situaiton. Leukosight, Inc had bee a privately held biopharmaceutical company developing a novel line of anti-inflammatory therapeutics to address the medical needs of patients with acute or chronic autoimmune/inflammatory diseases. The firm's website looks functional - profile of personnel etc - but appears to be a Canadian Pharmacy offering the firm's products. LeukoSightâs approach to treating inflammatory diseases had been to âreprogramâ white blood cells (leukocytes) to secrete immunoregulatory rather than immunostimulatory molecules. The therapeutics being developed at LeukoSight are potentially less toxic and more powerful than existing technologies, which are typically directed at inhibiting inflammatory mediators. Initial disease targets include multiple sclerosis and other autommune/inflammatory diseases. The first anti-inflammatory compound developed by LeukoSight is in pre-clinical trials. In small animal models of multiple sclerosis the administration of this product reverses paralysis and restores ambulatory function. A derivative of this product can also prevent the depletion of platelets during idiopathic thrombocytopenic purpura (ITP). The goal of LeukoSight is to develop products that enable patients with autoimmune diseases to lead healthy li
